PDCD1 and cancer: Recent successes in immune checkpoint blockade such as targeting CTLA-4 (cytotoxic T-lymphocyte antigen 4) and/or PD-1/PD-L (programmed cell death 1/PD-1 ligand) have fueled the treatment for cancers [5].